Vesicle size and transmitter release at the frog neuromuscular junction when quantal acetylcholine content is increased or decreased.
We investigated whether the synaptic vesicles at the neuromuscular junction change size when their acetylcholine (ACh) content is altered. The size of the miniature endplate potential (MEPP) increased 3- or 4-fold in preparations pre-treated in a hypertonic solution in which the anion was gluconate. We measured the dimensions of synaptic vesicles in such preparations and in controls. The size of the vesicles and size distribution were indistinguishable. Quanta contained about half of the usual amount of ACh in preparations stimulated in the presence of hemicholinium-3, an inhibitor of choline uptake, or in NH(4)(+), which diminishes the proton gradient for ACh uptake into the vesicles. Neither treatment changed the size of the synaptic vesicles. ACh content and vesicle size were both decreased in preparations stimulated in (-)-vesamicol, an inhibitor of ACh uptake in vesicles. Since the other inhibitors decreased ACh content by a similar amount without altering vesicle size, (-)-vesamicol may decrease vesicle size by acting on another target. We also found that a hypertonic solution in which the anion was aspartate increased quantal size similar to gluconate. Both anions have high hydration energy and a large volume. When these treatments increased quantal size the mean 20-80 % rise time of MEPPs recorded with an extracellular electrode was 170 micros. In the controls it was 97 micros. Perhaps some of the added ACh is bound within the vesicles, which slows the rise. Our major conclusion is that ACh content can change notably without any change in the size of the synaptic vesicles.
Van der Kloot
William
W
Department of Physiology and Biophysics, SUNY at Stony Brook, Stony Brook, NY 11794-8661, USA. wvanderkloot@post.harvard.edu
Molgó
Jordi
J
Cameron
Roger
R
Colasante
Cesare
C
D000109:Acetylcholine / Q000378:metabolism*; D000465:Algorithms; D000818:Animals; D001224:Aspartic Acid / Q000494:pharmacology; D055598:Chemical Phenomena; D002627:Chemistry, Physical; D004566:Electrodes; D004594:Electrophysiology; D005942:Gluconates / Q000494:pharmacology; D006982:Hypertonic Solutions; D066298:In Vitro Techniques; D008564:Membrane Potentials / Q000502:physiology; D008854:Microscopy, Electron; D009045:Motor Endplate / Q000378:metabolism / Q000648:ultrastructure; D009469:Neuromuscular Junction / Q000378:metabolism* / Q000648:ultrastructure*; D018377:Neurotransmitter Agents / Q000378:metabolism*; D018408:Patch-Clamp Techniques; D011894:Rana pipiens; D013572:Synaptic Vesicles / Q000378:metabolism* / Q000648:ultrastructure*
D005942:Gluconates; D006982:Hypertonic Solutions; D018377:Neurotransmitter Agents; D001224:Aspartic Acid; D000109:Acetylcholine